Dermatology has a long-standing affinity for acronyms. From AGEP (acute generalized exanthematous pustulosis) to XP (xeroderma pigmentosum), acronyms have become a part of our dermatology lexicon, perhaps occasionally to the consternation of our colleagues in other specialties. In this issue, Brau-Javier et al1 describe a patient with a severe pustular skin disease called “DIRA ” —an acronym for “deficiency of the interleukin 1 (IL-1) receptor antagonist, ” which we first described in 9 pediatric patients in 2009.2 As its name suggests, DIRA is a new autoinflammatory disease linked to activation of the IL-1 pathway (Figure), joining the ranks of other IL-1 –associated conditions with a prominent dermatologic component, foremost the cryopyrin-associated periodic fever syndromes (CAPS) —familial cold –induced autoinflammatory syndrome (FCAS), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (NOMID).3
Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and New Insights Into Pathways of Skin InflammationWhat's in a Name?. Arch Dermatol. 2012;148(3):381–384. doi:10.1001/archdermatol.2011.3014
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.